Duopharma concludes supply deal for 6.4m doses of Sputnik V vaccine

Duopharma Biotech said the supply of the 6.4 million doses of the Sputnik V vaccine is subject to the approval by the Drug Control Authority of Malaysia, as well as other terms and conditions of supply.

KUALA LUMPUR: Duopharma Biotech Bhd has concluded the supply agreements with the Malaysian Government and Russian Direct Investment Fund (RDIF) for the supply of 6.4 million doses of the Sputnik V vaccine.

In a statement on Tuesday, it said the supply of the vaccine is subject to the approval of the vaccine by the Drug Control Authority of Malaysia, as well as other terms and conditions of supply.